P3.03-019 Activity of PARP Inhibitor in NSCLC with Germline and Somatic Mutation and in Silico Chemotherapy Lethality
Carmélia Maria Noia Barreto(Instituto de Medicina Avançada), N Yamaguchi(Hospital Israelita Albert Einstein), Pedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), M.F. Manfrivato(Instituto de Medicina Avançada), Raphael B. Parmigiani(Hospital Sírio-Libanês), Keigo Kobayashi(Osaka Gakuin University), Fernanda Priscila Alves da Silva(Hospital Israelita Albert Einstein), Virgílio Souza e Silva(Instituto de Medicina Avançada), P. Tamura(Instituto de Medicina Avançada), M. Yaksic(Instituto de Medicina Avançada), Tiago Costa de Pádua(Universidade Federal de São Paulo), F. Di Silverio(Sapienza University of Rome), Massimiliano Spada(Instituto de Medicina Avançada), L. Zapata(Beneficência Portuguesa de São Paulo), L. Naraki(Instituto de Medicina Avançada)
Cited by 0
Related Papers
Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine
|Nature Genetics|1994|380
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung Cancer
|JAMA Oncology|2018|125
High Pressure NQR Measurement in CeCu<sub>2</sub>Si<sub>2</sub> up to Sudden Disappearance of Superconductivity
|Journal of the Physical Society of Japan|2008|78